Cyclerion Therapeutics shares fall 13.85% premarket after announcing a transformational relaunch as a neuropsychiatric company.

jueves, 25 de septiembre de 2025, 6:43 am ET1 min de lectura
CYCN--
Cyclerion Therapeutics, Inc. dropped 13.85% in premarket trading, following the company's announcement of a transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement.

Cyclerion Therapeutics shares fall 13.85% premarket after announcing a transformational relaunch as a neuropsychiatric company.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios